Literature DB >> 17486319

Involvement of alpha1-adrenergic receptors in tranylcypromine enhancement of nicotine self-administration in rat.

Anne-Sophie Villégier1, Shahrdad Lotfipour, James D Belluzzi, Frances M Leslie.   

Abstract

RATIONALE: The mechanisms mediating tobacco addiction remain elusive. Nicotine, the psychoactive component in tobacco, is generally believed to be the main cause of reward and addiction. However, tobacco smoke contains thousands of constituents, some of which may interact with nicotine to enhance reward. It has previously been shown that monoamine oxidase (MAO) inhibition, known to result from smoking, can enhance nicotine self-administration. The aim of the present study was to evaluate the role of noradrenergic systems in mediating this enhancement of nicotine reward.
OBJECTIVE: The objective of this study was to test the hypothesis that MAO inhibitor pretreatment enhances nicotine self-administration by activation of noradrenergic pathways that regulate dopamine release in the nucleus accumbens (NAc).
METHODS: The effect of prazosin (0.0625-0.5 mg/kg, i.p.), a specific alpha1-adrenergic receptor antagonist, was examined on male rats pretreated with tranylcypromine (3 mg/kg), an irreversible inhibitor of MAO A and B. Acquisition of nicotine (10 mug kg(-1) inj(-1), i.v.) self-administration behavior was examined over a 5-day period. Nicotine (60 mug kg(-1) inj(-1), i.v.)-induced increase in NAc extracellular dopamine levels was examined by in vivo microdialysis in non-self-administering animals.
RESULTS: We have shown that (1) tranylcypromine enhances nicotine self-administration, (2) prazosin pretreatment blocks both the acquisition and the expression of nicotine self-administration, and (3) prazosin pretreatment diminishes nicotine-induced dopamine release in the NAc.
CONCLUSION: These data indicate that the stimulation of alpha1-adrenergic receptors is critical for tranylcypromine enhancement of nicotine reward and suggest a critical interplay between the noradrenergic and dopaminergic systems in tobacco addiction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17486319     DOI: 10.1007/s00213-007-0799-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.415


  64 in total

1.  Diversity and distribution of nicotinic acetylcholine receptors in the locus ceruleus neurons.

Authors:  C Léna; A de Kerchove D'Exaerde; M Cordero-Erausquin; N Le Novère; M del Mar Arroyo-Jimenez; J P Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

Review 2.  The adolescent brain and age-related behavioral manifestations.

Authors:  L P Spear
Journal:  Neurosci Biobehav Rev       Date:  2000-06       Impact factor: 8.989

3.  Differential effects of chronic antidepressants in behavioural tests of beta-adrenergic and GABAB receptor function.

Authors:  D J McManus; A J Greenshaw
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors.

Authors:  W X Shi; C L Pun; X X Zhang; M D Jones; B S Bunney
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

5.  Nicotinic acetylcholine receptor-mediated release of [3H]norepinephrine from developing and adult rat hippocampus: direct and indirect mechanisms.

Authors:  F M Leslie; K A Gallardo; M K Park
Journal:  Neuropharmacology       Date:  2002-04       Impact factor: 5.250

6.  A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation.

Authors:  R Biberman; R Neumann; I Katzir; Y Gerber
Journal:  Addiction       Date:  2003-10       Impact factor: 6.526

7.  A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation.

Authors:  Tony P George; Jennifer C Vessicchio; Angelo Termine; Peter I Jatlow; Thomas R Kosten; Stephanie S O'Malley
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382

8.  Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system.

Authors:  J L Andersson; M Marcus; G G Nomikos; T H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

9.  Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels.

Authors:  G Griebel; O Curet; G Perrault; D J Sanger
Journal:  Neuropharmacology       Date:  1998-07       Impact factor: 5.250

10.  Nicotine-induced activation of locus coeruleus neurons--an analysis of peripheral versus central induction.

Authors:  G Engberg; M Hajos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-05       Impact factor: 3.000

View more
  19 in total

Review 1.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

2.  Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

Authors:  Benoit Forget; Carrie Wertheim; Paola Mascia; Abhiram Pushparaj; Steven R Goldberg; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

3.  Effect of doxazosin on stress reactivity and the ability to resist smoking.

Authors:  Terril L Verplaetse; Andrea H Weinberger; Lindsay M Oberleitner; Kathryn Mz Smith; Brian P Pittman; Julia M Shi; Jeanette M Tetrault; Meaghan E Lavery; Marina R Picciotto; Sherry A McKee
Journal:  J Psychopharmacol       Date:  2017-04-25       Impact factor: 4.153

Review 4.  Behavioral mechanisms underlying nicotine reinforcement.

Authors:  Laura E Rupprecht; Tracy T Smith; Rachel L Schassburger; Deanne M Buffalari; Alan F Sved; Eric C Donny
Journal:  Curr Top Behav Neurosci       Date:  2015

5.  Combat posttraumatic stress disorder, substance use disorders, and traumatic brain injury.

Authors:  Kathleen T Brady; Peter Tuerk; Sudie E Back; Michael E Saladin; Angela E Waldrop; Hugh Myrick
Journal:  J Addict Med       Date:  2009-12       Impact factor: 3.702

Review 6.  Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence.

Authors:  Terril L Verplaetse; Andrea H Weinberger; Philip H Smith; Kelly P Cosgrove; Yann S Mineur; Marina R Picciotto; Carolyn M Mazure; Sherry A McKee
Journal:  Nicotine Tob Res       Date:  2015-03-11       Impact factor: 4.244

7.  Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats.

Authors:  Edward D Levin; Susan Slade; Michael Johnson; Ann Petro; Kofi Horton; Paul Williams; Amir H Rezvani; Jed E Rose
Journal:  Eur J Pharmacol       Date:  2008-10-17       Impact factor: 4.432

8.  Bupropion and nicotine enhance responding for nondrug reinforcers via dissociable pharmacological mechanisms in rats.

Authors:  Matthew I Palmatier; Melissa E Levin; Kara L Mays; Eric C Donny; Anthony R Caggiula; Alan F Sved
Journal:  Psychopharmacology (Berl)       Date:  2009-09-17       Impact factor: 4.530

9.  Lobeline attenuates progressive ratio breakpoint scores for intracranial self-stimulation in rats.

Authors:  Paul J Wellman; Audrea E Elliott; Stephanie Barbee; Chelsie N Hollas; P Shane Clifford; Jack R Nation
Journal:  Physiol Behav       Date:  2007-12-31

10.  The α2-adrenergic receptor agonist, clonidine, reduces alcohol drinking in alcohol-preferring (P) rats.

Authors:  Dennis D Rasmussen; Laura Alexander; Julia Malone; David Federoff; Janice C Froehlich
Journal:  Alcohol       Date:  2014-07-14       Impact factor: 2.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.